The use of glucagon-like peptide-1 receptor agonists is likely to increase the risks of inadequate bowel preparation for colonoscopy, according to a study published Feb. 12 in The American Journal of ...
A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!
It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...
As demand remains high for GLP-1 drugs, primary care physicians are concerned about the risks of patients using third-party ...
More than 36 million Americans have type 2 diabetes, a condition primarily attributed to the body's cells not responding to ...
Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide Database lock completed Topline data readout ...
As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...
Health and Me on MSN2d
GLP-1 Drugs Could Be Used To Treat Chronic Kidney DiseaseA latest research led by Dr Shuyao Zhang, an assistant professor of internal medicine at UT Southwestern in Dallas reveal the ...
Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...
Though highly effective, medications for the prevention of chronic kidney disease progression are under-utilized, emphasizing the need for better use of prognostic tools.
A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...
Doctors emphasize the importance of regular checkups with a primary care provider and simple tests that could detect heart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback